Article Information
History
- August 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- John Schrom1,
- Carina Marquez1,
- Chung-Yu Wang3,
- Aditi Saxena3,
- Anthea M. Mitchell3,
- Salu Ribeiro5,
- Genay Pilarowski3,
- Robert Nakamura4,
- Susana Rojas5,
- Douglas Black1,
- Maria G. Contreras Oseguera5,
- Edgar Castellanos Diaz5,
- Joselin Payan5,
- Susy Rojas5,
- Diane Jones5,
- Valerie Tulier-Laiwa6,
- Aleks Zavaleta6,
- Jacqueline Martinez5,
- Gabriel Chamie1,
- Carol Glaser4,
- Kathy Jacobsen4,
- Maya Petersen7,
- Joseph DeRisi*,3 and
- Diane Havlir*,1,†
- 1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
- 2Department of Biochemistry and Biophysics, University of California San Francisco, CA 94143, USA
- 3Chan Zuckerberg Biohub, San Francisco, CA 94158, USA
- 4California Department of Public Health, Richmond, CA 94804, USA
- 5Unidos en Salud, San Francisco, CA 94143, USA
- 6Unidos en Salud and Latino Task Force, San Francisco, CA 94143, USA
- 7Division of Biostatistics, University of California, Berkeley, Berkeley, CA 94720, USA
- ↵†Corresponding author: Diane Havlir, MD, University of California, San Francisco, 995 Potrero Avenue, CA, diane.havlir{at}ucsf.edu
↵* These authors contributed equally to this work.
Posted August 18, 2022.
Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges
